gastric cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Patients who are admitted to outpatient department of gastroenterology or general surgery at Showa University Fujigaoka Hospital 2) Patients with histologically confirmed gastric cancer 3) Patients with clinical progress I to III who meet the indication for gastrectomy according to the 5th edition of the Guideline for Gastric Cancer Treatment 4)Patients who are 20 years or older and have PS0 or 1 at the time of obtaining consent 5)Patients who gave their informed consent to participate in this trial
Exclusion criteria
Exclusion criteria: 1) Patients with residual gastric cancer 2) Patients with gastrointestinal obstruction due to tumor 3) Patients who received preoperative chemotherapy or radiation therapy for gastric cancer 4) Patients who perform simultaneous resection of other organs other than gallbladder 5) Patients with infectious diseases that require systemic treatment 6) Patients who have comorbidies, or who are taking oral medication that interferes with the determination of efficacy in measuring the number of white blood cells and lymphocytes. 7) Patients with serious liver/renal disorders or cardiopulmonary diseases that may affect the safety evaluation of drugs 8) Patients who have been given Chinese herbal medicines 4 weeks before the start of the study 9)Patients who have a history of allergy to herbal medicine 10) Patients who are judged to be ineligible by the research doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change rate of skeletal muscle mass and body weight 1, 3 and 6 months after gastrectomy | — |
Secondary
| Measure | Time frame |
|---|---|
| Perioperative systemic inflammation markers, body composition analysis, grip strength, postoperative complications, surgery-related death | — |
Countries
Japan
Contacts
Showa University Fujigaoka Hospital Department of Gastroenterological and General Surgery